Genetically engineered biologics to treat psoriasis. Experience with ustekinumab in an adolescent with severe psoriasis

Modern pathogenetic therapy of psoriasis is the use suppressive methods aimed to suppress immune reactions in dermis, synovia, enthesis and eliminate imbalance between anti-inflammatory pro-inflammatory cytokines, chemokines. Today, genetically engineered biological drugs are one most promising pharmacotherapy achievements for management psoriasis, psoriatic arthritis group immunosuppressive agents. Knowing mechanisms that underlie development these diseases allows us today highly selectively target top key links immunopathogenetic cascade using biologicals, while barely affecting protective factors patient’s system unlike standard backbone (what referred as traditional) therapy. The treatment children adolescents practically involves same adults. However, them used paediatric practice conditions which they not clearly indicated, studies on their efficacy safety still missing. Currently, it possible treat with drugs. Ustekinumab, etanercept, adalimumab, secukinumab, ixekizumab approved moderate severe Russian Federation. In practice, drug ustekinumab effective, safe convenient delivery (short induction cycle, rare infusions during maintenance therapy). article describes case study effective a 17-year-old patient severe, continuously recurrent psoriasis. targeted therapy, including drugs, increasingly being childhood Moreover, there now more supporters among dermatologists who believe can be prescribed first-line adolescents.